Through our disease intelligence service, MDoutlook, Arcas has have provided insight and support for several news items since the summer:
* An article was published in the journal Value-Based Cancer Care in August 2011 about the cost implications for novel therapies in the treatment of non-small cell lung cancer (NSCLC). MDoutlook provided key insight on how the US and global community of medical oncologists will shift their management of NSCLC based on new information presented at ASCO 2011.(Article VBCC 08-2011)
* This month OBR published an article featuring immediate market insight delivered by MDoutlook to gauge the clinical impact of the recent FDA decision to revoke marketing authorization of bevacizumab (Avastin®) in HER-2 negative metastatic Breast Cancer. The article can be read here.
MDOUTLOOK, the global oncology intelligence platform, provides crucial insight into the dynamic role of clinicians involved in treating today’s oncology patient. You can read more about MDoutlook here. If you would like to talk to us or schedule a demo, please contact us at [email protected]